Haemonetics (HAE) Q3 2026

Q4 2026 Q3 2026 Q2 2026 Q1 2026

Earnings

Haemonetics delivered a solid fiscal third-quarter beat, with adjusted EPS of $1.31 clearing the $1.25 consensus by 4.77% and revenue of $338.97 million topping estimates by 1.88%, even as reported sales slipped 2.8% year-over-year. The headline decl… Read more Haemonetics delivered a solid fiscal third-quarter beat, with adjusted EPS of $1.31 clearing the $1.25 consensus by 4.77% and revenue of $338.97 million topping estimates by 1.88%, even as reported sales slipped 2.8% year-over-year. The headline decline was largely a function of the ongoing wind-down of CSL Plasma disposable sales and the prior-year divestiture of the Whole Blood product line, which masked an underlying organic ex-CSL revenue gain of 7.5% and reflected the company's deliberate shift toward higher-margin offerings. That portfolio transformation showed up clearly in GAAP gross margin, which expanded to 59.7% from 55.5% a year ago, helping lift adjusted operating margin to 26.3%. Free cash flow more than doubled to $74.20 million. A soft patch in Interventional Technologies, where revenue fell 11.4%, drew analyst attention, though management outlined targeted recovery steps including a planned U.S. Launch of PerQseal Elite. Encouraged by the momentum, Haemonetics raised its full-year adjusted EPS guidance to $4.90-$5.00 and lifted its free cash flow outlook to $200-$220 million.